The other researchers in the field, rightfully skeptical as they have seen other high profile trials crash and burn ClinicalTrials.gov lists the trial as Phase 2, interventional, with start in late October 2025 and estimated completion in 2026
It is absorbed intact and has no offensive taste or smell
Supplied as a research peptide in a sterile glass vial for laboratory research use only
Its primary actions include: Increasing slow-wave (delta) sleep the deepest, most physically restorative sleep stage Modulating corticotropin-releasing hormone (CRH) reducing the HPA axis signalling that keeps cortisol elevated Influencing LH and somatostatin release both relevant to testosterone and growth hormone secretion Antioxidant activity preclinical data suggests DSIP has direct free-radical scavenging properties (3) Thermoregulatory effects potentially lowering basal body temperature in a manner consistent with natural sleep onset The net effect is not sedation
Medicare Part D coverage for anti-obesity medications remains limited pending TROA legislation
These weight loss medications are an excellent option for individuals seeking a different approach to weight loss, as they are highly effective when used in conjunction with a balanced diet and regular exercise